Zuan T. Lin
651 Dongfeng East Road
Guangzhou, 510060, China
Guangzhou, 510060, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy.
Journal: iScience
Published: January 12, 2023
PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
Journal: Frontiers in immunology
Published: August 09, 2022
Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies.
Journal: Cancer chemotherapy and pharmacology
Published: April 13, 2022
Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer.
Journal: Journal of cancer research and clinical oncology
Published: January 23, 2022
A CT-based radiomics model to predict subsequent brain metastasis in patients with ALK-rearranged non-small cell lung cancer undergoing crizotinib treatment.
Journal: Thoracic cancer
Published: January 10, 2022
Correction to: Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus.
Journal: Cancer immunology, immunotherapy : CII
Published: December 06, 2021
Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 18, 2021
Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus.
Journal: Cancer immunology, immunotherapy : CII
Published: July 22, 2021
Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer.
Journal: Frontiers in immunology
Published: July 06, 2021
Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 29, 2021
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy.
Journal: Translational lung cancer research
Published: March 07, 2021
Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy.
Journal: Frontiers in oncology
Published: October 26, 2020
Last Updated: 09/26/2026